Related Experiment Video

Updated: Aug 16, 2025

Describing a Transcription Factor Dependent Regulation of the MicroRNA Transcriptome
07:23

Describing a Transcription Factor Dependent Regulation of the MicroRNA Transcriptome

Published on: June 15, 2016

8.5K

Role of STAT3 and NRF2 in Tumors: Potential Targets for Antitumor Therapy

Yanjun Tian1, Haiqing Liu2, Mengwei Wang3

  • 1Medical Laboratory of Jining Medical University, Jining Medical University, Jining 272067, China.

Molecules (Basel, Switzerland)
|December 23, 2022
PubMed

Insights

Signal transducer and activator of transcription 3 (STAT3) and nuclear factor erythroid-derived 2-like 2 (NRF2) are key regulators overactivated in tumors. Their interactions offer promising targets for novel antitumor drug development to improve patient survival.

Area of Science:

  • Molecular Biology
  • Oncology
  • Drug Discovery

Background:

  • Signal transducer and activator of transcription 3 (STAT3) and nuclear factor erythroid-derived 2-like 2 (NRF2) are complex transcription regulators involved in numerous physiological processes.
  • Both STAT3 and NRF2 are frequently overactivated in various types of cancer, indicating their significant role in tumorigenesis.

Purpose of the Study:

  • To review the critical roles of STAT3 and NRF2 in the tumor microenvironment.
  • To explore the interactions between STAT3 and NRF2 in regulating tumor progression.
  • To identify potential antitumor drug targets based on these transcription factors and their interplay.

Main Methods:

  • Literature review of existing studies on STAT3 and NRF2 in cancer.
  • Analysis of the molecular mechanisms underlying STAT3 and NRF2 functions.
  • Examination of the crosstalk between STAT3 and NRF2 in the tumor microenvironment.

Main Results:

  • STAT3 and NRF2 play pivotal roles in various aspects of tumor progression.
  • The interaction between STAT3 and NRF2 influences tumor development and the tumor microenvironment.
  • Dysregulation of these transcription factors is a hallmark of many cancers.

Conclusions:

  • STAT3 and NRF2 represent crucial targets for the development of novel anticancer therapeutics.
  • Targeting the interaction between STAT3 and NRF2 may offer a promising strategy for cancer treatment.
  • Further research into these transcription factors could lead to improved patient outcomes and survival rates.
Keywords:
NRF2STAT3antitumor therapysignal transductiontumor

More Related Videos

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo08:19

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Published on: July 20, 2019

6.0K
Merging Absolute and Relative Quantitative PCR Data to Quantify STAT3 Splice Variant Transcripts11:19

Merging Absolute and Relative Quantitative PCR Data to Quantify STAT3 Splice Variant Transcripts

Published on: October 9, 2016

15.0K

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
7.8K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.8K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K